Results 131 to 140 of about 169 (169)

Nitazoxanide for chronic hepatitis C

Cochrane Database of Systematic Reviews, 2014
Hepatitis C infection is a disease of the liver caused by the hepatitis C virus. The estimated number of chronically infected people with hepatitis C virus worldwide is about 150 million people. Every year, another three to four million people acquire the infection. Chronic hepatitis C is a leading cause of liver-related mortality and morbidity.
Kristiana Nikolova, Janus Christian Jakobsen, Christian Gluud, Berit Grevstad   +3 more
openaire   +3 more sources

Hepatitis C (chronic).

BMJ clinical evidence, 2007
About 60% to 85% of people infected with hepatitis C virus will go on to develop chronic hepatitis C, which is now believed to affect 3% of the world's population.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions in treatment-naïve people with chronic hepatitis C infection, but ...
Abdul, Mohsen, Suzanne, Norris
openaire   +3 more sources

Chronic Hepatitis C in Pregnancy

Obstetrics & Gynecology, 2008
To estimate outcomes, to determine whether appropriate follow-up was performed for pregnant patients with hepatitis C virus (HCV), and to show that maternal and neonatal complications would be higher in the HCV-positive group.We compared pregnant women from a drug dependence and treatment program who were HCV antibody-positive with those who were HCV ...
Sanjeev Arora, Clifford Qualls, Jeffrey C. Dunkelberg, Kimberly K. Leslie, Eliza Berkley   +4 more
openaire   +2 more sources

The Prevalence of Hepatic Granulomas in Chronic Hepatitis C

Journal of Clinical Gastroenterology, 2004
Hepatic granulomas are not usual findings in chronic hepatitis C. A few studies addressing the frequency of hepatic granulomas in chronic hepatitis C reported it as less than 10%. The presence of it has been suggested to predict a favorable response to interferon treatment.
Tozun, N, Ozbay, G, Kanat, M, Tabak, F, Celikel, CA, Uraz, S, Mert, A, Tahan, V, Ozaras, R, Senturk, H, Avsar, E   +10 more
openaire   +4 more sources

Treatment of chronic hepatitis C

Journal of Hepatology, 1991
alpha-Interferon given subcutaneously at doses between 1-3 million units leads to responses in about 50% of patients suffering from chronic hepatitis C. A 24-week treatment is frequently (approx. 50%) followed by relapses reducing the percentage of lasting responders to approx. 20%.
openaire   +3 more sources

Hepatitis C virus genotypes in chronic hepatitis C of children

Journal of Viral Hepatitis, 1996
SUMMARY.Several hepatitis C virus (HCV) genotypes have been recently identified and genotype 1b has been correlated with severe liver disease and a poor response to interferon therapy. HCV infection in children is an interesting model for evaluation of the relationship between HCV genotypes and liver disease, because of its relatively short duration ...
BORTOLOTTI, FLAVIA, VAJRO P, BALLI F, GIACCHINO R, CRIVELLARO C, BARBERA C, PONTISSO, PATRIZIA, NEBBIA C, ZANCAN, LUCIA, BERTOLINI A, ALBERTI, ALFREDO   +10 more
openaire   +6 more sources

Bicyclol for chronic hepatitis C

Cochrane Database of Systematic Reviews, 2006
Bicyclol is a novel synthetic 'anti-hepatitis' drug, used in China for chronic hepatitis B. Until now, systematic reviews of bicyclol therapy have not been performed.To study the benefits and harms of bicyclol for patients with chronic hepatitis B.We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (July 2005), The Cochrane Central
T, Wu, H, Roger, L, Xie, G, Liu, B, Hao
openaire   +4 more sources

Antifibrotics for Chronic Hepatitis C

Clinics in Liver Disease, 2009
Development and testing of antifibrotic agents for the treatment of chronic hepatitis C have generally been targeted toward hepatic stellate cells, transforming growth factor-beta, the inflammatory response, or extracellular matrix accumulation. Although several agents such as interferon-gamma, long-term pegylated interferon, and caspase inhibitors ...
openaire   +3 more sources

Economics of chronic hepatitis B and hepatitis C

Journal of Hepatology, 2007
Although not all patients develop progressive liver disease, chronic hepatitis B and chronic hepatitis C infections cause substantial morbidity and mortality worldwide. To address this need, many new antiviral treatments have become available over the past 10 years.
Arathi Rajendra, John B. Wong
openaire   +2 more sources

Hepatic sarcoidosis associated with chronic hepatitis C

Journal of Gastroenterology, 2002
A 57-year-old woman with sarcoidosis was referred because of the appearance of multiple small low-attenuation areas in the liver on computed tomography (CT). A liver biopsy specimen showed chronic active hepatitis accompanied by sarcoid granulomas. The patient received prednisolone and, later, interferon-alpha.
Sumiya Eto, Takeshi Fujisaki, Shinichiro Mine, Yoshiya Tanaka, Norihiro Ohnari, Shinwa Yamada   +5 more
openaire   +3 more sources